List of Invega Sustenna drug patents
Invega Sustenna is owned by Janssen Pharms.
Invega Sustenna contains Paliperidone Palmitate.
Invega Sustenna has a total of 1 drug patent out of which 0 drug patents have expired.
Invega Sustenna was authorised for market use on 31 July, 2009.
Invega Sustenna is available in suspension, extended release;intramuscular dosage forms.
Invega Sustenna can be used as treatment of schizophrenia; treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s).
The generics of Invega Sustenna are possible to be released after 26 January, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(8 years from now) | |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia; Treatment of schizoaffective disorder as a monotherapy and as an adjunct to mood stabilizers or antidepressants; Dosing regimen for the treatment of schizoaffective disorder in adults as a monotherapy and as an adjunct to mood stabilizers or antidepressants by administering two loading doses of paliperidone palmitate followed by maintenance dose(s); Dosing regimen for the treatment of schizophrenia in adults by administering two loading doses of paliperidone palmitate followed by maintenance dose(s)
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic